Company profile ACET

Adicet Bio Inc
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifyi...ng and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v Show More
Quarter analysis & expected interestLast update: February 08 2024 12:50:07.

After 39 days of this quarter the interest is at 148.0. Based on that we can calculate that during remaining 52 days it will total up to 345.0.
Adicet Bio expected interest is significantly higher compared to previous quarter (+336.7%) and same quarter last year (+148.2%).

YearQ1Q2Q3Q4
20197
49
600.0% QoQ
20
-59.2% QoQ
38
90.0% QoQ
2020 25
257.1% YoY -34.2% QoQ
70
42.9% YoY 180.0% QoQ
68
240.0% YoY -2.9% QoQ
21
-44.7% YoY -69.1% QoQ
2021 83
232.0% YoY 295.2% QoQ
37
-47.1% YoY -55.4% QoQ
77
13.2% YoY 108.1% QoQ
87
314.3% YoY 13.0% QoQ
2022 118
42.2% YoY 35.6% QoQ
180
386.5% YoY 52.5% QoQ
143
85.7% YoY -20.6% QoQ
125
43.7% YoY -12.6% QoQ
2023 139
17.8% YoY 11.2% QoQ
218
21.1% YoY 56.8% QoQ
154
7.7% YoY -29.4% QoQ
79
-36.8% YoY -48.7% QoQ
2024 148
6.5% YoY 87.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Adicet Bio search interestLast update: February 08 2024 12:50:07.
Correlation coefficient between keyword and revenue is -0.01
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:50:09.

The average 5 years interest of Adicet Bio was 7.23 per week.
The last year interest of Adicet Bio compared to the last 5 years has changed by 69.99%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 407.85%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adicet Bio therapies to provide analysis

Correlation between past revenue and Adicet Bio therapies search interest

There is not enough data for Adicet Bio therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adicet Bio therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ADI-001 therapy to provide analysis

Correlation between past revenue and ADI-001 therapy search interest

There is not enough data for ADI-001 therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ADI-001 therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adicet Bio clinical trials to provide analysis

Correlation between past revenue and Adicet Bio clinical trials search interest

There is not enough data for Adicet Bio clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adicet Bio clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adicet Bio jobs to provide analysis

Correlation between past revenue and Adicet Bio jobs search interest

There is not enough data for Adicet Bio jobs to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adicet Bio jobs to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adicet Bio Massachusetts to provide analysis

Correlation between past revenue and Adicet Bio Massachusetts search interest

There is not enough data for Adicet Bio Massachusetts to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adicet Bio Massachusetts to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adicet Bio near me to provide analysis

Correlation between past revenue and Adicet Bio near me search interest

There is not enough data for Adicet Bio near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adicet Bio near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:50:16.

After 39 days of this quarter the interest is at 29.0. Based on that we can calculate that during remaining 52 days it will total up to 68.0.
Adicet Bio -stock -company expected interest is significantly lower compared to previous quarter (-69.5%) and same quarter last year (-60.9%).

YearQ1Q2Q3Q4
2019123
82
-33.3% QoQ
247
201.2% QoQ
184
-25.5% QoQ
2020 95
-22.8% YoY -48.4% QoQ
227
176.8% YoY 138.9% QoQ
215
-13.0% YoY -5.3% QoQ
276
50.0% YoY 28.4% QoQ
2021 99
4.2% YoY -64.1% QoQ
74
-67.4% YoY -25.3% QoQ
39
-81.9% YoY -47.3% QoQ
243
-12.0% YoY 523.1% QoQ
2022 361
264.6% YoY 48.6% QoQ
395
433.8% YoY 9.4% QoQ
261
569.2% YoY -33.9% QoQ
273
12.3% YoY 4.6% QoQ
2023 174
-51.8% YoY -36.3% QoQ
445
12.7% YoY 155.7% QoQ
314
20.3% YoY -29.4% QoQ
223
-18.3% YoY -29.0% QoQ
2024 29
-83.3% YoY -87.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Adicet Bio -stock -company search interestLast update: February 08 2024 12:50:15.
Correlation coefficient between keyword and revenue is -0.2
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:50:17.

The average 5 years interest of Adicet Bio -stock -company was 16.78 per week.
The last year interest of Adicet Bio -stock -company compared to the last 5 years has changed by 25.39%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 61.1%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ACET
Earnings date: 2024-03-13 After close
Company name: Adicet Bio Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T20:00:00Z

BusinessWire
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

2026-05-13T20:01:00Z

BusinessWire
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

2026-03-23T11:23:23Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Adicet Bio, Lowers Price Target to $27

2026-03-13T12:52:01Z

Analyst Upgrades
Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $100

2026-03-12T20:00:00Z

BusinessWire
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

2026-01-30T12:00:00Z

BusinessWire
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-21T11:33:53Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $50

2025-12-26T13:30:00Z

BusinessWire
Adicet Bio Announces Reverse Stock Split

2025-11-28T19:23:00Z

BusinessWire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

2025-11-07T12:38:50Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $9

2025-11-05T21:01:00Z

BusinessWire
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

2025-10-31T20:59:00Z

BusinessWire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2025-10-28T11:00:00Z

BusinessWire
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

2025-10-16T11:00:00Z

BusinessWire
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

2025-10-10T20:06:01-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Adicet Bio, Inc. (0001720580) (Issuer)